Summary
Pfizer Inc. (PFE) announced on December 7, 2017, a series of significant debt management transactions. These include a private offer to exchange its outstanding £1.5 billion 6.500% Notes due 2038 for new debt securities, alongside an offer to purchase these same 2038 Notes for cash. The company is also initiating a cash tender offer for its outstanding €2 billion 5.750% Notes due 2021, coupled with a consent solicitation to amend the terms of these 2021 Notes and their governing indenture.
Key Highlights
- 1Pfizer is proactively managing its debt portfolio through exchange offers and cash tender offers.
- 2The company is seeking to refinance its outstanding £1.5 billion 6.500% Notes due 2038.
- 3Pfizer is also making an offer to purchase its €2 billion 5.750% Notes due 2021 for cash.
- 4A consent solicitation is underway for the 2021 Notes to amend terms and the associated indenture.
- 5These transactions are detailed in an Offering Memorandum, Offer to Purchase, and Consent Solicitation Statement.
- 6The transactions were announced via a press release filed as an exhibit to the 8-K.
Frequently Asked Questions
The primary purpose is for Pfizer to manage its outstanding debt. This includes refinancing a specific series of Sterling-denominated notes and making offers to purchase Euro-denominated notes, potentially optimizing its capital structure and debt maturity profile.
The transactions involve Pfizer's outstanding £1,500,000,000 6.500% Notes due 2038 and its outstanding €2,000,000,000 5.750% Notes due 2021.
For the 2038 Notes, Pfizer is conducting a private offer to exchange them for newly issued debt securities and also a separate offer to purchase them for cash.
The consent solicitation is a request to the holders of the 2021 Notes for their approval to certain amendments to the terms of those notes and to the underlying indenture that governs them.